BioXcel Therapeutics (BTAI) Announces Completion of Pre-NDA Meeting with FDA for BXCL501 for Acute Treatment of Agitation in Patients with Schizophrenia and Bipolar Disorders

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/24/2026

1. SPCX
2. FDX
3. META
4. ABBV
5. SPY
6. IBM
7. NKE
8. MU
9. USO
10. NVDA

Go back to BioXcel Therapeutics (BTAI) Announces Completion of Pre-NDA Meeting with FDA for BXCL501 for Acute Treatment of Agitation in Patients with Schizophrenia and Bipolar Disorders

BioXcel Therapeutics (BTAI) Misses Q3 EPS by 27c

November 12, 2020 7:06 AM EST

BioXcel Therapeutics (NASDAQ: BTAI) reported Q3 EPS of ($1.07), $0.27 worse than the analyst estimate of ($0.80).

Building on the successful data readout from the Phase 3 SERENITY trials earlier this year, we have continued to make substantial progress with BXCL501s development as a treatment for agitation across neuropsychiatric conditions, stated Vimal Mehta, Chief Executive Officer of BTI.... More